| OCB+ | OCB− | Whole group | p value |
---|---|---|---|---|
N (f/m) | 50 (34/16) | 40 (28/12) | 90 (62/28) | 0.511 |
Age (years) | 42.5 ± 10.4 (19–67) | 42.4 ± 11.2 (17–69) | 42.5 ± 10.7 (17–69) | 0.943 |
Years from onset to diagnosis | 3.0 ± 5.1 (0–21) | 2.6 ± 3.9 (0–17) | 2.8 ± 4.6 (0–21) | 0.356 |
Years from diagnosis to enrolment | 7.8 ± 5.2 (0–20) | 7.9 ± 6.4 (0–22) | 7.9 ± 5.7 (0–22) | 0.918 |
Years from onset to enrolment (disease duration) | 10.8 ± 7.0 (1–31) | 10.5 ± 7.3 (1–29) | 10.7 ± 7.1 (1–31) | 0.878 |
EDSS at diagnosis | 1.5 (0–3.0) | 1.0 (0–3.5) | 1.5 (0–3.5) | 0.645 |
EDSS at enrolment | 2.8 (1.0–8.0) | 1.5 (0–6.5) | 2.0 (1.0–8.0) | <0.0001 |
RRMS/SPMS at enrolment | 35/15 | 36/4 | 71/19 | 0.018 |
Time to SPMS transition in months | 123 ± 23 (98–187) | 183 ± 13 (165–198) | 136 ± 33 (98–198) | <0.0001 |
Cognitive impairment CN/mCI/sCI | 30/9/11 | 34/5/1 | 64/14/12 | 0.013 |
CL number at enrolment | 6.1 ± 6.1 (0–24) | 2.2 ± 2.8 (0–11) | 4.4 ± 5.3 (0–24) | <0.0001 |
WMLV at enrolment (cm3) | 7.1 ± 3.6 (1.1–16.4) | 6.5 ± 4.1 (1.3–18.1) | 6.8 ± 4.0 (1.1–18.1) | 0.258 |
Treatment until now | ||||
 None | 0 | 5 | 5 | 0.033 |
 Only 1° linea | 34 | 28 | 62 | |
 At least 2° linea | 11 | 6 | 17 | |
 At least 3° linea | 5 | 1 | 6 |